Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2007 1
2009 3
2010 7
2011 7
2012 8
2013 3
2014 2
2015 6
2016 6
2017 5
2018 4
2019 1
2020 3
2021 2
2022 2
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
Potkin SG, Cohen M, Panagides J. Potkin SG, et al. J Clin Psychiatry. 2007 Oct;68(10):1492-500. doi: 10.4088/jcp.v68n1004. J Clin Psychiatry. 2007. PMID: 17960962 Clinical Trial.

Compared with placebo, improvements on CGI-S and PANSS positive subscale scores were significantly greater with both asenapine (p < .01 and p = .01) and risperidone (p < .005 and p < .05). ...CONCLUSION: Asenapine was effective and well tolerated in

…
Compared with placebo, improvements on CGI-S and PANSS positive subscale scores were significantly greater with both asenapine …
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Kane JM, et al. J Clin Psychopharmacol. 2010 Apr;30(2):106-15. doi: 10.1097/JCP.0b013e3181d35d6b. J Clin Psychopharmacol. 2010. PMID: 20520283 Clinical Trial.
In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity). ...Post hoc anal …
In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine a …
Asenapine pharmacokinetics and tolerability in a pediatric population.
Dogterom P, Riesenberg R, de Greef R, Dennie J, Johnson M, Pilla Reddy V, Miltenburg AM, Findling RL, Jakate A, Carrothers TJ, Troyer MD. Dogterom P, et al. Drug Des Devel Ther. 2018 Aug 30;12:2677-2693. doi: 10.2147/DDDT.S171475. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30214156 Free PMC article. Clinical Trial.
RESULTS: The PK of asenapine showed rapid absorption (T(max) ~1 hour) with an apparent terminal half-life between 16 and 32 hours. ...Simulation-based estimates of C(max) and AUC(0-12) were similar for pediatric and adult patients; age, body-mass index, race, and sex were …
RESULTS: The PK of asenapine showed rapid absorption (T(max) ~1 hour) with an apparent terminal half-life between 16 and 32 hours. .. …
Quantification of asenapine and three metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: application to a phase I clinical trial with asenapine in healthy male subjects.
de Boer T, Meulman E, Meijering H, Wieling J, Dogterom P, Lass H. de Boer T, et al. Biomed Chromatogr. 2012 Feb;26(2):156-65. doi: 10.1002/bmc.1640. Epub 2011 May 6. Biomed Chromatogr. 2012. PMID: 21557265 Clinical Trial.
The development and validation of methods for determining concentrations of the antipsychotic drug asenapine (ASE) and three of its metabolites [N-desmethylasenapine (DMA), asenapine-N(+) -glucuronide (ASG) and 11-O-sulfate-asenapine (OSA)] in human plasma us …
The development and validation of methods for determining concentrations of the antipsychotic drug asenapine (ASE) and three of its m …
Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070).
Suzuki K, Castelli M, Komaroff M, Starling B, Terahara T, Citrome L. Suzuki K, et al. J Clin Psychopharmacol. 2021 May-Jun 01;41(3):286-294. doi: 10.1097/JCP.0000000000001383. J Clin Psychopharmacol. 2021. PMID: 33734167 Free PMC article. Clinical Trial.
Asenapine area under the curve values at HP-3070 3.8 and 7.6 mg/24 hours doses were similar to those for sublingual asenapine 5 and 10 mg twice-daily doses, respectively, whereas peak exposure (maximum observed plasma concentration) was significantly lower. ...HP-30 …
Asenapine area under the curve values at HP-3070 3.8 and 7.6 mg/24 hours doses were similar to those for sublingual asenapine …
Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder.
Landbloom RL, Mackle M, Wu X, Kelly L, Snow-Adami L, McIntyre RS, Mathews M, Hundt C. Landbloom RL, et al. J Affect Disord. 2016 Jan 15;190:103-110. doi: 10.1016/j.jad.2015.06.059. Epub 2015 Sep 25. J Affect Disord. 2016. PMID: 26496015 Clinical Trial.
Others included difference in asenapine versus placebo in the Clinical Global Impression Scale for Bipolar Severity (CGI-BP-S) and rate of YMRS responders. ...Both asenapine doses had statistically superior improvement in mean change in CGI-BP-S score …
Others included difference in asenapine versus placebo in the Clinical Global Impression Scale for Bipolar Severity (CGI-BP-S) …
Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.
Mahajan V, Arora M, Tandon VR, Gillani Z, Praharaj SK. Mahajan V, et al. J Clin Psychopharmacol. 2019 Jul/Aug;39(4):305-311. doi: 10.1097/JCP.0000000000001064. J Clin Psychopharmacol. 2019. PMID: 31205195 Clinical Trial.
The objective of the study was to compare the efficacy and safety of asenapine and olanzapine when used in combination with divalproex in patients with acute mania. ...Higher weight gain, increased sleep and appetite, and tremors were seen in the olanzapine-treated patient …
The objective of the study was to compare the efficacy and safety of asenapine and olanzapine when used in combination with divalproe …
Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations.
Gerrits MG, de Greef R, Dogterom P, Peeters PA. Gerrits MG, et al. J Clin Pharmacol. 2012 May;52(5):757-65. doi: 10.1177/0091270011404028. Epub 2011 May 31. J Clin Pharmacol. 2012. PMID: 21628604 Clinical Trial.
It is extensively metabolized; the 2 main metabolites are asenapine N-glucuronide and N-desmethyl-asenapine. The authors investigated the pharmacokinetic interactions between asenapine and valproate in an open-label, randomized, 2-way crossover study. ...Bloo …
It is extensively metabolized; the 2 main metabolites are asenapine N-glucuronide and N-desmethyl-asenapine. The authors inves …
A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.
Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. Kane JM, et al. J Clin Psychiatry. 2011 Mar;72(3):349-55. doi: 10.4088/JCP.10m06306. Epub 2011 Feb 22. J Clin Psychiatry. 2011. PMID: 21367356 Clinical Trial.
RESULTS: Of 700 enrolled patients treated with open-label asenapine, 386 entered (asenapine, n = 194; placebo, n = 192) and 207 completed (n = 135; n = 72) the double-blind phase. Times to relapse/impending relapse and discontinuation for any reason were significant …
RESULTS: Of 700 enrolled patients treated with open-label asenapine, 386 entered (asenapine, n = 194; placebo, n = 192) and 20 …
Asenapine in the Treatment of Bipolar Depression.
El-Mallakh RS, Nuss S, Gao D, Gao Y, Ahmad SC, Schrodt C, Adler C. El-Mallakh RS, et al. Psychopharmacol Bull. 2020 Mar 12;50(1):8-18. Psychopharmacol Bull. 2020. PMID: 32214517 Free PMC article. Clinical Trial.
OBJECTIVES: Asenapine, a potent serotonin 7 (5-HT(7)) receptor antagonist, was examined for efficacy as an antidepressant in depressed bipolar subjects. ...Due to the large fraction of subjects with the short form, the hypothesis that the SF-5HTTR might increase asenapi …
OBJECTIVES: Asenapine, a potent serotonin 7 (5-HT(7)) receptor antagonist, was examined for efficacy as an antidepressant in depresse …
51 results